Low molecular weight heparin in the treatment of severe acute pancreatitis: a multiple centre prospective clinical study

Asian J Surg. 2009 Apr;32(2):89-94. doi: 10.1016/s1015-9584(09)60017-8.

Abstract

Objective: To study the effect of low molecular weight heparin (LMWH) in the treatment of severe acute pancreatitis (SAP).

Methods: A total of 265 SAP patients were randomly divided into two groups: firstly, the conventional treatment group (C group, n = 130; and secondly the conventional treatment plus the LMWH treatment group (LT group, n = 135). The clinical parameters, laboratory parameters and computed tomography (CT) score of pancreatic necrosis (CTSPN) in the two groups were compared.

Results: On admission, all the clinical parameters, laboratory parameters and CTSPN in the two groups were not significantly different (p > 0.05). However, after treatment, in LT group, the clinical presentation improvement rate and laboratory parameters improvement were significantly higher than those in C group (p < 0.05-0.01), and the acute physiology and chronic health evaluation (APACHE) II score, complication rate, mortality and mean hospital stay in LT group were obviously lower than those in C group (p < 0.05-0.01). The CT score in LT group was much lower than that in C group (p < 0.05). Two weeks after treatment FBI decreased obviously in C group, but not in LT group, and no haemorrhagic complications occurred.

Conclusions: LMWH can enhance the effect of conventional treatment for SAP, and can markedly decrease the mortality of SAP. LMWH is a simple, safe, economic and effective method for treatment of SAP. It is can be used in every hospital.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • APACHE
  • Acute Disease
  • Adolescent
  • Adult
  • Aged
  • Anticoagulants / therapeutic use*
  • Child
  • Female
  • Heparin, Low-Molecular-Weight / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Multiple Organ Failure / epidemiology
  • Pancreatitis / drug therapy*
  • Prospective Studies
  • Young Adult

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight